Technical Briefing: Launch Event of 'Assessing the Value of Biopharmaceutical Innovation in Key Therapy Areas in Middle Income Countries'
29 January 2014,
IFPMA rolled out an independent study, Assessing the Value of Biopharmaceutical Innovation in Key Therapy Areas in Middle Income Countries, during the recent SCP meeting in Geneva. Conducted by Charles River Associates (CRA), the study demonstrates the value that innovative medicines have for patients and society by enhancing treatment options and reducing overall healthcare costs.
Despite these benefits, the report concludes that there remains enormous untapped potential of adopting innovative medicines more widely in middle-income countries. This can be achieved by national prioritization, investments in healthcare infrastructure and building better epidemiological and cost databases for effective evaluation of therapies.
Tim Wilsdon, CRA Vice President, presented the findings to an audience of over 70 participants and a panel of two commentators elaborating on the value of medicines. Panelists included Dr. Evelyne Sauty, Director of Clinical and Medical Affairs at MSD and Mr. Greg Perry, Executive Director of the Medicines Patent Pool. IFPMA's Andrew Jenner moderated the event.
The CRA study focused on five therapy areas: coronary heart disease (CHD), depression, diabetes II, HIV/AIDS, and rotavirus infection. Wilsdon shared research showing that significant decreases in hospitalization costs and mortality rates in countries like Brazil and Australia can be attributed to the introduction of selected medicines. The panelists complemented CRA’s findings and provided their experiences. Dr. Sauty highlighted R&D challenges and complexity by illustrating how MSD researched, developed, and provided a new vaccine preventing rotavirus, while Mr. Perry cited development of certain HIV/AIDS treatments in addressing the collaborative nature of many innovation programs. Finally, to inform and enrich SCP discussions on patent and health, this study provides significant empirical evidence by considering the wider value of medicines rather than focusing on cost and price alone.